Ironwood Pharmaceuticals (NASDAQ:IRWD) Rating Lowered to Hold at StockNews.com

StockNews.com downgraded shares of Ironwood Pharmaceuticals (NASDAQ:IRWDFree Report) from a buy rating to a hold rating in a report issued on Monday morning.

Separately, Craig Hallum cut their price target on Ironwood Pharmaceuticals from $18.00 to $14.00 and set a buy rating on the stock in a report on Friday, May 10th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of Moderate Buy and a consensus price target of $18.40.

Check Out Our Latest Stock Report on IRWD

Ironwood Pharmaceuticals Stock Performance

NASDAQ:IRWD opened at $6.46 on Monday. Ironwood Pharmaceuticals has a 52 week low of $5.47 and a 52 week high of $15.70. The firm’s fifty day moving average is $6.51 and its 200-day moving average is $9.48. The firm has a market cap of $1.01 billion, a P/E ratio of -0.95 and a beta of 0.52.

Ironwood Pharmaceuticals (NASDAQ:IRWDGet Free Report) last issued its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.02) EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.20). Ironwood Pharmaceuticals had a negative net margin of 254.41% and a negative return on equity of 28.45%. The firm had revenue of $74.90 million for the quarter, compared to the consensus estimate of $105.75 million. During the same period last year, the company posted $0.25 EPS. The business’s revenue was down 28.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that Ironwood Pharmaceuticals will post 0.56 earnings per share for the current year.

Insider Activity at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, Director Catherine Moukheibir sold 44,426 shares of the company’s stock in a transaction on Thursday, June 6th. The stock was sold at an average price of $6.36, for a total value of $282,549.36. Following the completion of the transaction, the director now owns 84,207 shares in the company, valued at approximately $535,556.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Ironwood Pharmaceuticals news, Director Catherine Moukheibir sold 44,426 shares of Ironwood Pharmaceuticals stock in a transaction dated Thursday, June 6th. The shares were sold at an average price of $6.36, for a total value of $282,549.36. Following the sale, the director now owns 84,207 shares of the company’s stock, valued at $535,556.52. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Julie Mchugh sold 22,766 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $6.29, for a total transaction of $143,198.14. Following the sale, the director now owns 139,528 shares of the company’s stock, valued at approximately $877,631.12. The disclosure for this sale can be found here. 12.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in Ironwood Pharmaceuticals by 21.8% during the 1st quarter. Vanguard Group Inc. now owns 19,521,366 shares of the biotechnology company’s stock worth $170,031,000 after purchasing an additional 3,487,821 shares in the last quarter. Armistice Capital LLC lifted its holdings in shares of Ironwood Pharmaceuticals by 64.9% in the fourth quarter. Armistice Capital LLC now owns 5,700,000 shares of the biotechnology company’s stock worth $65,208,000 after buying an additional 2,244,000 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its position in shares of Ironwood Pharmaceuticals by 40.8% in the first quarter. Jacobs Levy Equity Management Inc. now owns 4,235,580 shares of the biotechnology company’s stock valued at $36,892,000 after acquiring an additional 1,226,377 shares during the period. Kynam Capital Management LP purchased a new position in Ironwood Pharmaceuticals during the first quarter valued at approximately $14,154,000. Finally, Charles Schwab Investment Management Inc. increased its holdings in Ironwood Pharmaceuticals by 4.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,288,653 shares of the biotechnology company’s stock worth $14,742,000 after acquiring an additional 57,859 shares during the period.

Ironwood Pharmaceuticals Company Profile

(Get Free Report)

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.

Read More

Analyst Recommendations for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.